SpringBrand lets marketing, sales and support teams build AI agents by describing the task in plain English, with 10,000+ plugins and APIs under one account
United States, 15th Oct 2026 —SpringBrand lets marketing, sales and support teams build an AI agent by describing the task in plain English, with no node graph to draw and nothing to self-host. SpringBrand is an AI agent builder with a marketplace of plugins and APIs.
The product is made for go-to-market teams that already use AI but still spend time setting up and maintaining automations. Gartner expects 40% of enterprise applications to be integrated with task-specific AI agents by the end of 2026, up from less than 5% in 2025. SpringBrand gives those teams an easy way to build an agent without first learning a workflow tool.
Describe the task instead of drawing it
Canvas-based tools ask someone to design a workflow graph node by node. SpringBrand starts from the task. A user states the goal, the inputs, any constraints and what a useful result looks like, and the agent finds the plugins and APIs to run it. Each plugin packages a professional task as a reusable workflow, so building a workflow is as easy as describing it once and running it again.
One account for 10,000+ tools
The marketplace covers search, SEO data, social platforms, sales data and media generation, from providers such as Google, Ahrefs, Semrush, TikTok, Apollo and ElevenLabs. The company says it offers more than 10,000 APIs and plugins and ready-to-use workflows for more than 500 go-to-market scenarios. One SpringBrand account and one credit balance cover them all.
What teams build with it
Marketing teams build agents for SEO automation, competitor analysis and content creation. Sales teams use agents for meeting prep, lead qualification and CRM work. Support and ecommerce teams have ready-made agents for customer support and Shopify stores.
How it works
A user connects an agent, describes the outcome and lets it pick a matching capability. Before it runs, the user fills in missing details and approves any requested access or external action. SpringBrand agents search, read and draft; posting, sending and account changes stay with the user. Finished runs show their sources, dates and limitations for review.
Why SpringBrand built it
“Teams don’t need another workflow to build and maintain. They need an agent that gets the work done,” said Trevor, Tech Leader of SpringBrand. “We built SpringBrand so that building an agent is as simple as describing the task, and the person who knows the work stays in control of what goes out.”
SpringBrand is available now at https://springbrand.ai/ . The Free plan includes 100 credits a month and needs no credit card.
About SpringBrand
SpringBrand is an AI agent builder with a marketplace of plugins and APIs, operated by SPRINGBRAND, INC. Learn more at https://springbrand.ai/ .
Australian fertiliser maker Complete Grow has launched Orchid Grow & Bloom, a two-stage, urea-free orchid fertiliser that matches feeding to each stage of an orchid’s growth. In a side-by-side comparison with a Dural, NSW orchid grower, Complete Grow recorded blooms 15% larger.
Sydney, NSW, Australia, 15th Oct 2026 — Australian fertiliser manufacturer Complete Grow has launched Orchid Grow & Bloom, a two-stage liquid orchid fertiliser system that matches feeding to each stage of an orchid’s growth.
Orchid Grow (NPK 14-3-11) feeds roots, leaves and pseudobulbs during active vegetative growth. Orchid Bloom (NPK 8-18-24) is used from the first visible flower spike until the final flower drops.
Both concentrates are urea-free, made in Australia and contain calcium, magnesium and six trace elements.
Orchid Grow & Bloom at a glance
Use Orchid Grow: when there is no flower spike, bud or flower
Use Orchid Bloom: from the first visible flower spike until the final flower drops
Application rate: 1 mL per litre of water at every watering
Monthly care: water with plain water once a month
Pack size: two 500 mL double-strength concentrates
Feed made: 1,000 litres from one pack
Suitable for: Phalaenopsis, cymbidiums, dendrobiums, cattleyas, oncidiums and vandas
Formulation: urea-free, with calcium, magnesium and six trace elements
What makes Orchid Grow & Bloom different from other orchid fertilisers
Orchid Grow & Bloom differs from single-formula orchid fertilisers in five ways:
Two formulas, one for each stage. Many orchid fertilisers use one NPK ratio all year. Orchid Grow (NPK 14-3-11) is nitrogen-led for roots, leaves and pseudobulbs. Orchid Bloom (NPK 8-18-24) is high in phosphorus and potassium for spikes, buds and flowers.
Double-strength concentrate. Both formulas carry twice the label NPK concentration of the standard liquid orchid fertilisers Complete Grow benchmarked, so 1 mL makes a full litre of feed. Each 500 mL bottle makes 500 litres, and the pack makes 1,000 litres.
Urea-free. Neither formula contains urea, a nitrogen source common in general-purpose plant foods.
Calcium and magnesium in both formulas. Orchids watered with rainwater still get both nutrients at every feed.
Six trace elements. Iron, manganese, zinc, boron, copper and molybdenum in every feed, with iron, manganese and zinc in chelated form.
Why use a different orchid fertiliser for growth and flowering?
During active growth, orchids build new roots, leaves and, depending on the variety, pseudobulbs. Nitrogen supports vegetative growth. Once a flower spike appears, the plant directs more of its resources to the spike, buds and flowers, where phosphorus and potassium matter more.
Orchid Grow & Bloom uses the plant itself as the feeding calendar: use Orchid Grow until the first flower spike appears, switch to Orchid Bloom until the final flower drops, then return to Orchid Grow.
In most of Australia, that means Orchid Grow through summer and into autumn, then Orchid Bloom from the first spike through winter and spring. Because the spike sets the switch, not the calendar, the system suits orchids that flower early or late. Complete Grow’s free orchid care guide shows how to spot the first flower spike and when to switch fertilisers.
“Orchids have different nutritional priorities during vegetative growth and flowering, yet many are fed with the same formula all year,” said Daniel Azzi, Plant Nutrition and Horticultural Specialist at Complete Grow.
“We wanted to make orchid feeding straightforward. Feed the stage the plant is in, and let the flower spike tell you when to switch.”
A urea-free orchid fertiliser with calcium, magnesium and trace elements
Orchid Grow and Orchid Bloom are both urea-free. Each label lists calcium at 1.2% and magnesium at 0.5% (w/v). Iron, manganese and zinc are chelated with EDTA, which keeps them soluble in the feed.
Calcium supports new plant tissue, and magnesium is a central component of chlorophyll. Both matter most when orchids are watered with low-mineral water, including rainwater.
Each of the six trace elements does a specific job:
Iron: needed to make chlorophyll and keep new leaves green
Manganese: drives photosynthesis and activates enzymes
Zinc: supports the growth hormones behind new leaves and roots
Boron: builds cell walls and supports flower and pollen development
Copper: activates enzymes and strengthens plant tissue
Molybdenum: helps the plant convert nitrate into usable nitrogen
Independent research shows that the form of nitrogen matters to moth orchids. A peer-reviewed study published in HortScience in 2008 found that high nitrate-to-ammonium ratios promoted the growth and flowering of a hybrid Phalaenopsis grown in two potting media, with the best growth when 75% of the nitrogen was supplied as nitrate. Growth declined when ammonium was oversupplied.
That research did not test Complete Grow products or a two-stage feeding system. It is provided as background on nitrogen nutrition in Phalaenopsis.
Orchid fertiliser results from a commercial grower in Dural
Complete Grow ran an internal side-by-side comparison at a commercial orchid and flower-growing operation in Dural, NSW.
The control group stayed on the orchid fertiliser the grower had used in previous seasons. The second group followed the two-stage program: Orchid Grow during vegetative growth, then Orchid Bloom from flower-spike development.
Complete Grow recorded blooms 15% larger in the two-stage group than in the control group. The grower also observed more flowers staying presentable for longer, which extended their sales window.
“For a commercial grower, flowers that stay presentable for longer have a longer opportunity to be sold,” Azzi said. “That was the result we were most pleased to see.”
This result comes from one internal comparison run by Complete Grow, not an independent study. Results vary with orchid variety, growing conditions and care.
How to fertilise orchids with Orchid Grow & Bloom
Shake the bottle and mix 1 mL of concentrate per litre of water. Apply the diluted feed at every watering.
A 5 mL capful makes 5 litres of feed.
Once a month, water with plain water only to refresh the potting mix and keep roots healthy.
Orchid fertiliser FAQs
What is the best fertiliser for orchids?
The best fertiliser for orchids is a urea-free, two-stage feed: a nitrogen-led formula such as NPK 14-3-11 while the orchid grows roots and leaves, followed by a bloom formula such as NPK 8-18-24 from the first flower spike until the last flower drops, with calcium and magnesium included in both.
When should I use Orchid Grow?
Use Orchid Grow when the orchid has no flower spike, buds or open flowers. Continue while the plant develops roots, leaves and pseudobulbs.
When should I switch to Orchid Bloom?
Switch to Orchid Bloom when the first flower spike becomes visible. Continue until the final flower drops, then return to Orchid Grow.
How can I tell a flower spike from a new root?
On a Phalaenopsis orchid, a new root has a rounded, smooth tip. A developing flower spike is flatter, with a mitten-shaped tip.
How often should you fertilise orchids?
Feed at every watering at 1 mL per litre of water, and water with plain water once a month.
Which orchids can use Orchid Grow & Bloom?
Orchid Grow & Bloom is formulated for commonly grown orchids, including moth orchids (Phalaenopsis), cymbidiums, dendrobiums, cattleyas, oncidiums and vandas, grown indoors, on patios or in shadehouses.
Availability
Orchid Grow & Bloom is available now as a pack of two 500 mL concentrates from the Complete Grow online store, with delivery across Australia.
About Complete Grow
Complete Grow is an Australian fertiliser company producing liquid and soluble plant nutrition for home gardeners, indoor plant growers, hydroponic growers and commercial operations.
Its range includes balanced NPK fertilisers, specialist orchid fertilisers, flowering and fruiting formulas, calcium and magnesium supplements and hydroponic nutrients. Complete Grow delivers throughout Australia, exports to Pacific Island markets and supplies wholesale customers in the United States and Europe.
Learn more at completegrow.com.au.
Media contact Daniel Azzi Plant Nutrition and Horticultural Specialist Complete Grow support@completegrow.com.au (02) 9053 1426 completegrow.com.au
Shane Devereux looks back on a specific moment from his baseball days at Malvern Prep and the way of thinking it left him with.
A Game That Did Not Go to Plan
Pennsylvania, USA, Oct 15, 2026, ZEX PR WIRE — Shane Devereux grew up around West Chester, Pennsylvania, and played baseball through his years at Malvern Prep. He says one memory from that stretch stuck with him more than any single win or loss.
“I remember a game where I was 0 for 3 and overthinking every single pitch,” Devereux says. “By the fourth at-bat, I wasn’t even thinking about the ball anymore. I was thinking about the first three at-bats.”
He says the at-bat that followed is the one he still thinks about. Not because it went well right away, but because of what changed in his approach before it did.
Going Back to What He Already Knew
Devereux says his coach didn’t give him a new tip or a mechanical fix between innings. The advice was simpler than that.
“He just told me to do what I always did in the cage,” Devereux says. “Same stance, same routine, same two practice swings. Nothing new. Just the version of me that shows up every day at practice.”
He says that reset is what actually worked. The next at-bat wasn’t a highlight, but it felt different, because he wasn’t trying to invent a better swing under pressure. He was running the one he had already built.
“That’s the part people miss,” Devereux says. “You don’t find your best self in the big moment. You just bring the version you already built.”
Why the Lesson Stuck Past Baseball
Devereux says he has carried that idea into other parts of life well past his playing days at Malvern. He points to habits around his own routines today: working out, cooking, spending time with friends and family.
“The days that go best for me aren’t the days I try something new,” he says. “They’re the days I just run my normal routine and don’t overthink it.”
He connects this to a theme that shows up in Atomic Habits, a book he counts among his influences. The idea that consistency compounds, and that the small, repeated version of something matters more than the occasional big effort, is one he says applies far beyond a batter’s box.
“I think people hear ‘trust your training’ and assume it’s a sports cliche,” Devereux says. “But it’s really just saying: the practice version of you is the real you. The pressure doesn’t change who you are, it just reveals whichever version you’ve actually built.”
What He Tells People Who Ask About It
Devereux says friends sometimes ask him how he stays level when something doesn’t go well right away, whether it’s a round of golf or anything else.
“My answer is always some version of the same thing,” he says. “Go back to the parts you know. Don’t reach for something new in the moment when you haven’t built it yet.”
He says this isn’t about lowering expectations. It’s about separating what you can control in a given moment from what you can’t.
“You can’t control whether the first three at-bats go your way,” Devereux says. “You can control whether you show up to the fourth one as yourself, instead of as someone panicking and trying to be a different hitter.”
A Story He Still Tells
Devereux says he doesn’t remember the final score of that Malvern Prep game. What stayed with him is the smaller moment: stepping back into the box and choosing the routine over the panic.
“It’s a small story,” he says. “But it’s the one I go back to when I need the reminder. Do the thing you already know how to do. Let that be enough.”
Shane Devereux grew up around West Chester, Pennsylvania, and attended Malvern Prep, where he played baseball, before going on to Penn State. He now lives in Malvern, Pennsylvania. Outside of his daily routine, he spends time cooking, working out, golfing, and following Chicago and Philadelphia sports teams.
Virginia, USA, Oct 15, 2026, ZEX PR WIRE— Travel can be a great way to take a break from everyday routines, explore new places, and spend time with the people who matter most. A little planning can help make any trip more enjoyable, whether it is a short weekend away or a longer vacation. Thinking about a few simple things before leaving can make the experience more relaxing and rewarding.
What Do You Want to Get Out of the Trip?
Before choosing a destination, it can be helpful to think about what you want from your trip. Some people enjoy sightseeing and exploring busy cities, while others prefer quiet places where they can relax. Knowing what you want to experience can help you choose a destination that fits your interests.
Having a general idea of your goals can also make planning easier. You do not need to have every detail figured out. Sometimes, simply knowing whether you want adventure, relaxation, or a change of scenery is enough to get started.
Who Will You Be Traveling With?
Traveling with friends or family can create opportunities to share experiences and make lasting memories. Visiting new places together can be a fun way to spend time with others and discover common interests.
Traveling alone can also be rewarding. It allows you to make your own plans, explore at your own pace, and decide how you want to spend your time. There is no single right way to travel. The best choice depends on your preferences and the type of experience you hope to have.
Why Is It Important to Make Time to Relax?
It can be tempting to fill a vacation with activities, attractions, and places to visit. While having plans can be helpful, leaving some free time can make a trip more enjoyable.
A relaxing afternoon at the beach, a walk through a park, or a quiet meal at a local restaurant can become a memorable part of a vacation. Taking breaks also allows you to enjoy your surroundings without feeling rushed.
Finding a balance between activities and relaxation can help you return home feeling refreshed rather than tired from a busy schedule.
How Can You Make the Most of New Experiences?
One of the best parts of traveling is having the opportunity to experience something different. Visiting a new city, trying local food, or learning about another culture can introduce you to new ideas and perspectives.
It is helpful to have a few places or activities in mind, but remaining flexible can also make a difference. Unexpected discoveries are often part of the enjoyment of traveling. Being open to different experiences can help make each trip feel unique.
What Will Make the Trip Memorable?
A meaningful trip does not have to involve expensive hotels, a packed schedule, or visiting every popular attraction. Often, the simplest moments can make an experience special.
Spending time with loved ones, enjoying a beautiful view, or discovering a place you have never visited before can all become lasting memories. Thinking about what you enjoy most can help you plan a trip that feels worthwhile.
Taking photos and keeping small reminders of your experiences can also be a nice way to look back on a vacation. However, it is just as important to enjoy the moment rather than feeling the need to document everything.
Keeping Travel Planning Simple
Planning a trip does not need to be complicated. Choosing a destination, setting a reasonable budget, deciding who will join you, and leaving room for flexibility can provide a good starting point.
Every traveler has different interests and priorities, so no single formula works for everyone. The goal is to create an experience that suits your needs and allows you to enjoy your time away.
With a little preparation and an open mind, travel can offer a welcome change of pace, opportunities to learn, and memories you can appreciate long after you return home.
Nine Years of Building Trusted Infrastructure for Wallets and Payments, for Humans and AI Agents
SINGAPORE, October 14, 2026 – Cobo, a trusted digital asset infrastructure company, today marks its ninth anniversary with “9 Stories,” a series of short films featuring founders, clients, partners, and team members sharing their experiences and perspectives in their own words. After nine years of delivering Wallet-as-a-Service (WaaS) and multi-chain solutions, Cobo has served more than 680 clients across nearly 50 countries and regions.
Founded in 2017 by blockchain pioneers Discus Fish and Dr. Changhao Jiang, Cobo has built trusted infrastructure with a focus on operational efficiency and risk management.
“What I hope never changes is our commitment to prioritizing long-term value over short-term trends, and making decisions about what to build based on what creates real value for our users,” said Dr. Changhao Jiang, Co-founder & CTO.
That philosophy continues to guide Cobo as it responds to emerging shifts in how digital assets are used and managed. In 2026, AI tools are enabling organizations to automate complex workflows and reduce reliance on traditional software while creating demand for secure, enforceable ways for AI agents to hold assets, execute payments, and manage treasury on-chain.
Cobo’s response is the Cobo Agentic Wallet (CAW), launched earlier this year as a non-custodial-by-default, MPC-secured wallet purpose-built for AI agents. It allows autonomous on-chain operations within human-defined boundaries enforced at the infrastructure level.
“To our clients: thank you for trusting Cobo and giving us the room to keep iterating. I believe a better future, perhaps beyond what we can imagine today, lies ahead, and we look forward to building it together,” said Discus Fish, Co-founder & CEO.
As it marks its ninth anniversary, Cobo looks back on key milestones, including a $13 million Series A in 2018, a $40 million Series B+ led by DST Global, IMO Ventures, and A&T Capital in 2021, the launch of WaaS, SOC 2 Type II (Big Four audited), and ISO 27001 certification.
New stories from the “9 Stories” series will be released over the coming weeks starting today. Watch them at https://www.cobo.com/9th.
About Cobo
Founded in 2017 and headquartered in Singapore, Cobo builds trusted infrastructure for wallets and payments, for humans and AI agents, with licensed entities in Hong Kong, Canada, and the United States. Cobo is SOC 2 Type II (Big Four audited) and ISO 27001 certified, and has secured billions in client assets with zero security incidents since 2017.
Investors In 50+ Countries Can Now Follow Verified Traders Automatically, Through The Mt4, Mt5 Or Dxtrade Account They Already Own
FX Junction, the social and copy trading platform, is making professional-grade trading strategies accessible to anyone with a brokerage account. Investors connect their existing MetaTrader 4, MetaTrader 5 or DXtrade account, choose from a roster of verified signal providers, and see those providers’ trades mirrored in their own account in real time. The model rests on one simple promise: FX Junction never holds client money. Every dollar stays with the investor’s own broker, under the investor’s own control.
Trading Stops Being A Solitary Pursuit
For years, retail trading has meant one person alone with a screen full of charts. FX Junction is built on the opposite idea. Its global community connects beginners and seasoned professionals, young and old, so that strategies, insight and experience can be shared across borders. A newcomer no longer has to learn everything the hard way; they can follow traders whose full record is public.
Up and running in four steps
Create an account. Registration takes minutes and requires no prior trading experience.
Connect an existing account. Investors link an MT4, MT5 or DXtrade account from virtually any major broker.
Choose whom to follow. Each signal provider has a verified performance history, with detailed analytics covering more than five years of data.
Let the platform do the work. Trades are replicated automatically, with latency the company puts below 0.1 seconds.
Built For Control, Not Blind Faith
FX Junction gives investors the tools to decide how much risk they take on. Position sizing, stop-loss settings and AI-assisted risk controls sit alongside 24/7 portfolio monitoring, live notifications and full reporting. Users can copy several traders at once across Forex, stocks, indices and commodities, more than 150 instruments in total, building a diversified portfolio from a single dashboard.
Because funds never move to FX Junction, investors keep the broker relationship they already trust. They can trade independently alongside their copied positions at any time.
More Than A Copy Button
FX Junction pairs automation with education and research. Its free Education Hub offers short courses on signal-provider analytics, the psychology of copying, and portfolio architecture. Daily market news, live technical analysis with entry, stop-loss and take-profit levels, and monthly model equity portfolios keep members informed. The October 2026 portfolio, for example, focuses on ten companies in nuclear generation, grid equipment and data-center power, the infrastructure behind surging AI electricity demand.
For investors who want a guiding hand, FX Junction offers annual support packages from $199 to $1,999 per year. Every tier includes MetaTrader and DXtrade training, performance-based guidance on signal providers, portfolio and diversification consultation, and risk and money management. Higher tiers add technical and fundamental analysis training, company results briefings and alerts when the investment outlook changes.
Experienced traders can also join the other side of the platform as signal providers, while businesses can work with FX Junction through API, white-label and referral programs.
About FX Junction
FX Junction is a social and copy trading platform that lets investors automatically replicate the trades of verified signal providers in their own MT4, MT5 or DXtrade accounts. Available in more than 50 countries and compatible with over 1,000 brokers, it combines automated copying with risk controls, market research and education, while client funds remain at the investor’s own broker. FX Junction is operated by FXJ LTD, Bonovo Road, P.B. 1257, Fomboni, Island of Mohéli, Comoros Union.
Risk warning: Trading leveraged products carries a high level of risk and may not be suitable for all investors. Past performance is no guide to future results, and investors may get back less than they invested. FX Junction does not provide investment advice. Company figures cited are as reported on fxjunction.com as of October 12, 2026.
Investors In 50+ Countries Can Now Follow Verified Traders Automatically, Through The Mt4, Mt5 Or Dxtrade Account They Already Own
FX Junction, the social and copy trading platform, is making professional-grade trading strategies accessible to anyone with a brokerage account. Investors connect their existing MetaTrader 4, MetaTrader 5 or DXtrade account, choose from a roster of verified signal providers, and see those providers’ trades mirrored in their own account in real time. The model rests on one simple promise: FX Junction never holds client money. Every dollar stays with the investor’s own broker, under the investor’s own control.
Trading Stops Being A Solitary Pursuit
For years, retail trading has meant one person alone with a screen full of charts. FX Junction is built on the opposite idea. Its global community connects beginners and seasoned professionals, young and old, so that strategies, insight and experience can be shared across borders. A newcomer no longer has to learn everything the hard way; they can follow traders whose full record is public.
Up and running in four steps
Create an account. Registration takes minutes and requires no prior trading experience.
Connect an existing account. Investors link an MT4, MT5 or DXtrade account from virtually any major broker.
Choose whom to follow. Each signal provider has a verified performance history, with detailed analytics covering more than five years of data.
Let the platform do the work. Trades are replicated automatically, with latency the company puts below 0.1 seconds.
Built For Control, Not Blind Faith
FX Junction gives investors the tools to decide how much risk they take on. Position sizing, stop-loss settings and AI-assisted risk controls sit alongside 24/7 portfolio monitoring, live notifications and full reporting. Users can copy several traders at once across Forex, stocks, indices and commodities, more than 150 instruments in total, building a diversified portfolio from a single dashboard.
Because funds never move to FX Junction, investors keep the broker relationship they already trust. They can trade independently alongside their copied positions at any time.
More Than A Copy Button
FX Junction pairs automation with education and research. Its free Education Hub offers short courses on signal-provider analytics, the psychology of copying, and portfolio architecture. Daily market news, live technical analysis with entry, stop-loss and take-profit levels, and monthly model equity portfolios keep members informed. The October 2026 portfolio, for example, focuses on ten companies in nuclear generation, grid equipment and data-center power, the infrastructure behind surging AI electricity demand.
For investors who want a guiding hand, FX Junction offers annual support packages from $199 to $1,999 per year. Every tier includes MetaTrader and DXtrade training, performance-based guidance on signal providers, portfolio and diversification consultation, and risk and money management. Higher tiers add technical and fundamental analysis training, company results briefings and alerts when the investment outlook changes.
Experienced traders can also join the other side of the platform as signal providers, while businesses can work with FX Junction through API, white-label and referral programs.
About FX Junction
FX Junction is a social and copy trading platform that lets investors automatically replicate the trades of verified signal providers in their own MT4, MT5 or DXtrade accounts. Available in more than 50 countries and compatible with over 1,000 brokers, it combines automated copying with risk controls, market research and education, while client funds remain at the investor’s own broker. FX Junction is operated by FXJ LTD, Bonovo Road, P.B. 1257, Fomboni, Island of Mohéli, Comoros Union.
Risk warning: Trading leveraged products carries a high level of risk and may not be suitable for all investors. Past performance is no guide to future results, and investors may get back less than they invested. FX Junction does not provide investment advice. Company figures cited are as reported on fxjunction.com as of October 12, 2026.
Boca Raton, Florida, October 14th, 2026, FinanceWire
Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi’s first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development
INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio’s investigational treatment for Alzheimer’s disease and other disease conditions.
The collaboration brings together INmune Bio’s data from pre-clinical research through four clinical trials and understanding of disease biology with QCi’s Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success.
The Stage 1 engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement also provides options for additional work as INmune Bio advances its clinical development programs.
“We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro,” said David Moss, Chief Executive Officer of INmune Bio. “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets. We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying pediatric approvals may earn a Priority Review Voucher.”
Together, the companies will build on INmune Bio’s research into XPro to explore where its approach to targeting inflammation may offer the greatest potential. XPro is designed to selectively inhibit soluble tumor necrosis factor (TNF), a protein involved in inflammation, while preserving other TNF functions important to the immune system. INmune Bio is investigating its potential in neurological and rare diseases where this targeted approach may offer a therapeutic benefit.
Using its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics, QCi will look for patterns and relationships across these datasets that could help researchers better understand treatment responses, identify promising patient populations and prioritize new indications for further study.
“This is a great example of what practical quantum computing can look like today,” said Yuping Huang, Chairman and Chief Executive Officer of QCi. “INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn. The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi.”
An important part of the program will be testing where quantum optimization adds value. The companies plan to compare results from QCi’s quantum optimization machine with appropriate conventional statistical and machine-learning methods, evaluating which approaches are best suited to different parts of the analysis.
The work is also intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.
For INmune Bio, the collaboration offers a new way to evaluate the broader potential of XPro and prioritize future development opportunities. For QCi, it represents an opportunity to showcase how its room-temperature, low-power quantum computing technology can be applied to complex, real-world problems in pharmaceutical research.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.
INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:
CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
XPro1595: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595 is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.
To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.
About Quantum Computing Inc.
Quantum Computing Inc. (Nasdaq: QUBT) is an integrated quantum photonics company developing and manufacturing technologies that use light to compute complex information, capture hard-to-detect signals and communicate more securely. QCi brings together quantum optics, integrated photonics, semiconductor manufacturing and advanced packaging to create a more direct path from advanced science to practical products.
QCi’s portfolio includes quantum machines, photonic chips, components, modules and subsystems, as well as foundry and advanced manufacturing services. Its technologies are designed to operate at room temperature and low power, without the specialized cooling infrastructure required by many quantum approaches. These advantages enable deployment across computing and AI, secure communications, sensing and imaging, aerospace and defense, and other demanding applications.
Headquartered in Hoboken, New Jersey, QCi has operations across the United States. By combining advanced physics, device engineering and scalable manufacturing, QCi is working to make quantum and advanced photonic technologies more accessible and useful in the real world.
To learn more about QCi and its approach to harnessing light for practical quantum computing, please visit www.quantumcomputinginc.com.
Forward Looking Statements:
InMune Bio Inc.
The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel, XPro and INKmune trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom, XPro1595 (XPro, pegipanermin), and INKmune have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Quantum Computing Inc.
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “enhance,” “intends,” “goal,” “objective,” “seek,” “attempt,” “aim to,” or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including QCi’s ability to use quantum optimization to analyze biomedical data, whether collaboration will generate relevant and valuable insights, the performance of the Dirac-3S in the intended application, the ability of quantum optimization to contribute to the development of new treatments, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward- looking statements to reflect changed conditions.
Contacts
Head of Investor Relations Daniel Carlson dcarlson@inmunebio.com Head of Investor Relations David Moskowtiz investors@quantumcomputinginc.com
Boca Raton, Florida, October 14th, 2026, FinanceWire
Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi’s first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development
INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio’s investigational treatment for Alzheimer’s disease and other disease conditions.
The collaboration brings together INmune Bio’s data from pre-clinical research through four clinical trials and understanding of disease biology with QCi’s Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success.
The Stage 1 engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement also provides options for additional work as INmune Bio advances its clinical development programs.
“We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro,” said David Moss, Chief Executive Officer of INmune Bio. “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets. We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying pediatric approvals may earn a Priority Review Voucher.”
Together, the companies will build on INmune Bio’s research into XPro to explore where its approach to targeting inflammation may offer the greatest potential. XPro is designed to selectively inhibit soluble tumor necrosis factor (TNF), a protein involved in inflammation, while preserving other TNF functions important to the immune system. INmune Bio is investigating its potential in neurological and rare diseases where this targeted approach may offer a therapeutic benefit.
Using its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics, QCi will look for patterns and relationships across these datasets that could help researchers better understand treatment responses, identify promising patient populations and prioritize new indications for further study.
“This is a great example of what practical quantum computing can look like today,” said Yuping Huang, Chairman and Chief Executive Officer of QCi. “INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn. The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi.”
An important part of the program will be testing where quantum optimization adds value. The companies plan to compare results from QCi’s quantum optimization machine with appropriate conventional statistical and machine-learning methods, evaluating which approaches are best suited to different parts of the analysis.
The work is also intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.
For INmune Bio, the collaboration offers a new way to evaluate the broader potential of XPro and prioritize future development opportunities. For QCi, it represents an opportunity to showcase how its room-temperature, low-power quantum computing technology can be applied to complex, real-world problems in pharmaceutical research.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.
INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:
CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
XPro1595: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595 is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.
To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.
About Quantum Computing Inc.
Quantum Computing Inc. (Nasdaq: QUBT) is an integrated quantum photonics company developing and manufacturing technologies that use light to compute complex information, capture hard-to-detect signals and communicate more securely. QCi brings together quantum optics, integrated photonics, semiconductor manufacturing and advanced packaging to create a more direct path from advanced science to practical products.
QCi’s portfolio includes quantum machines, photonic chips, components, modules and subsystems, as well as foundry and advanced manufacturing services. Its technologies are designed to operate at room temperature and low power, without the specialized cooling infrastructure required by many quantum approaches. These advantages enable deployment across computing and AI, secure communications, sensing and imaging, aerospace and defense, and other demanding applications.
Headquartered in Hoboken, New Jersey, QCi has operations across the United States. By combining advanced physics, device engineering and scalable manufacturing, QCi is working to make quantum and advanced photonic technologies more accessible and useful in the real world.
To learn more about QCi and its approach to harnessing light for practical quantum computing, please visit www.quantumcomputinginc.com.
Forward Looking Statements:
InMune Bio Inc.
The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel, XPro and INKmune trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom, XPro1595 (XPro, pegipanermin), and INKmune have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Quantum Computing Inc.
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “enhance,” “intends,” “goal,” “objective,” “seek,” “attempt,” “aim to,” or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including QCi’s ability to use quantum optimization to analyze biomedical data, whether collaboration will generate relevant and valuable insights, the performance of the Dirac-3S in the intended application, the ability of quantum optimization to contribute to the development of new treatments, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward- looking statements to reflect changed conditions.
Contacts
Head of Investor Relations Daniel Carlson dcarlson@inmunebio.com Head of Investor Relations David Moskowtiz investors@quantumcomputinginc.com
Seven of eight grades customer-certified and first 13 of 57 containers of ULVAC equipment landed in Pohang on the path to more than 10,000 metric tons of annual capacity; SmCo production equipment targeted for mid-2027 as DFARS 252.225-7052 extends its mine-to-magnet restriction to SmCo magnets on January 1, 2027
Evolution Metals & Technologies Corp. (“EM&T” or the “Company”) (Nasdaq: EMAT), a U.S.-based critical materials and advanced manufacturing company, today announced that its portfolio of eight sintered neodymium-iron-boron (“NdFeB”) rare earth magnet grades represents what the Company estimates to be approximately 75% of global sintered NdFeB magnet revenue and approximately 52% of global volume — placing EM&T squarely at the commercial center of the rare earth magnet market. The Company also reaffirmed its fiscal 2027 revenue guidance of $400 million to $460 million, announced that it expects to begin acquiring equipment to produce samarium cobalt (“SmCo”) magnets, the magnet class relied upon across U.S. military systems, by mid-2027, and confirmed it will respond to the U.S. Army’s sources sought notice for rare earth magnets.
The portfolio — N42SH, N48SH, N46SH, N35SH, N45H, N42H, N48M and N50M — spans the medium-, high- and super-high-temperature classes that drive the bulk of global magnet demand. Seven of the eight grades have already completed customer certification, led by N42SH, the single largest grade in the global market at an estimated 23% of sintered NdFeB revenue, now in commercial production at EM&T’s operations in Pohang, South Korea. The eighth grade, N48SH, is in the final stages of customer certification. Market share figures are Company estimates.
The portfolio’s revenue share exceeds its volume share by design: it is deliberately weighted toward the premium high-temperature grades that command the highest prices in the market. Its four super-high-temperature (“SH”) grades, rated to 150°C, incorporate heavy rare earths such as dysprosium and terbium to hold their magnetic strength under extreme heat, and alone are estimated to represent approximately 49% of global sintered NdFeB revenue on just 30% of volume. These are the grades specified for EV traction motors, wind turbine generators, aerospace generators and defense actuators — the most demanding, highest-value applications in the industry.
With certification largely complete, EM&T’s priority for 2027 is scale. Thirteen additional ULVAC sintered magnet production machines are being delivered to Pohang, where the first 13 of 57 containers of ULVAC equipment have already arrived. The expansion is expected to lift annual capacity to more than 10,000 metric tons, including approximately 6,000 metric tons of high-performance sintered magnets, as the Company optimizes all eight grades for yield, consistency and throughput. On that foundation, EM&T reaffirms its fiscal 2026 revenue guidance of $10 million to $11 million and its fiscal 2027 revenue guidance of $400 million to $460 million.
The planned SmCo line extends EM&T into the magnet class at the heart of U.S. defense systems. SmCo magnets retain their performance at temperatures beyond the reach of NdFeB and deliver superior corrosion resistance and thermal stability, making them the standard choice for guidance and control systems, aerospace actuators, and radar and satellite systems. The timing is deliberate. Effective January 1, 2027, DFARS 252.225-7052 extends its restriction on SmCo magnets across the entire supply chain, from ore through finished magnet, for qualifying U.S. defense deliveries, while samarium itself has been subject to China’s rare earth export licensing controls since April 2025. Demand for compliant, non-China SmCo supply is building now. The line will draw on the expertise of Kenji Konishi, EM&T’s Head of Magnet Engineering Production and former Vice President and Chief Technology Officer of JL MAG Rare Earth, whose background spans sintered NdFeB and SmCo magnet systems from alloy design through mass production.
That demand is already surfacing at the federal level. On September 28, 2026, the U.S. Army Contracting Command, Aberdeen Proving Ground, Tobyhanna Division, issued a sources sought notice to identify potential vendors of rare earth magnets, with responses due October 28, 2026. EM&T will respond to the notice.
“EM&T will be answering the U.S. Army’s call for rare earth magnets,” said Andrew Knaggs, President of EM&T. “In a highly unusual move, the U.S. Army appears to intend to acquire magnets directly for its defense apparatus and contractors. With seven customer-certified grades in production in Pohang and a SmCo line on the way, we believe EM&T is exactly the kind of supplier that requirement is looking for.”
“Three quarters of the value in the global sintered magnet market sits in the eight grades EM&T produces, and our customers have already certified seven of them,” said David Wilcox, Executive Chairman of EM&T. “We did not build this portfolio around the edges of the market. We built it around the center, weighted toward the super-high-temperature grades that EV, wind, aerospace and defense customers specify and pay a premium for. 2027 is about execution: optimizing those eight grades as our new ULVAC capacity takes Pohang past 10,000 metric tons, and adding samarium cobalt, the magnet the U.S. defense industrial base depends on where heat and stability matter most. With DFARS reaching SmCo magnets on January 1, 2027 and samarium already under Chinese export licensing, demand for compliant supply is building now, and EM&T intends to meet it at commercial scale.”
“We are growing, and the proof is on the ground in Pohang,” said Frank Moon, Chief Executive Officer of EM&T. “The first 13 of 57 containers of ULVAC equipment have arrived, seven of our eight grades carry customer certification, and our fiscal 2027 revenue guidance of $400 million to $460 million stands. These are not projections — they are milestones, and each one reflects production that is already scaling.”
“The grades in this portfolio are the product of years of development in high-performance sintered magnets, a segment approximately ten times the size of the bonded magnet market,” said Kenji Konishi, Head of Magnet Engineering Production at EM&T. “That development is now in production. We are growing output of grades our customers have already certified, and our SmCo line will be built on the same engineering foundation.”
About Evolution Metals & Technologies Corp.
Evolution Metals & Technologies Corp. (Nasdaq: EMAT) is a U.S.-based critical materials and advanced manufacturing company for rare earth permanent magnets, battery materials, and related critical minerals and technologies. By leveraging proven commercial-scale operations, advanced processing technologies, and strategic partnerships, EM&T operates what it believes is the only vertically integrated critical materials supply chain spanning end-of-life electronics and batteries, high-grade concentrates, and the manufacture of finished rare earth magnets (including high-performance rare earth magnets) and battery materials. For additional information, please visit investors.evolution-metals.com and follow the Company on LinkedIn.
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s fiscal 2026 revenue guidance of $10 million to $11 million and its fiscal 2027 revenue guidance of $400 million to $460 million and the assumptions underlying them; the completion and timing of customer certification of the Company’s N48SH grade; the Company’s estimates of the global market share represented by its sintered magnet grades; the Company’s plans to optimize production of its sintered magnet grades; the expected timing of the acquisition of equipment for, and the commencement of, samarium cobalt magnet production; the expansion of annual rare earth magnet production capacity in Pohang to more than 10,000 metric tons and the timing of delivery, installation and commissioning of ULVAC equipment; anticipated demand from defense, aerospace, automotive and industrial customers, including customers seeking DFARS-compliant supply; the January 1, 2027 effective date and scope of DFARS 252.225-7052; the Company’s intention to respond to the U.S. Army’s sources sought notice for rare earth magnets and any resulting procurement; and EM&T’s strategy, business plans and growth opportunities. These forward-looking statements, together with terms such as anticipate, expect, intend, may, will, should, believe, plan, positioned and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Market share figures in this press release are Company estimates and may differ from actual market conditions. The Company’s guidance is based on management’s current expectations and assumptions, including anticipated customer demand, and is not based on contracted volumes. Such risks include, among others, customer qualification requirements and timing; whether the U.S. Army issues a solicitation or awards any contract; delays in equipment delivery, installation and commissioning; the Company’s ability to obtain working capital and other financing on acceptable terms, or at all, and to continue as a going concern; the availability and cost of non-China rare earth feedstock, including samarium; the Company’s ability to secure purchase orders from existing and prospective customers at anticipated volumes and prices; changes in the DFARS 252.225-7052 effective date, scope, waiver practices, tariffs or other government policies; competition; rare earth pricing and currency fluctuations; the Company’s ability to achieve contemplated production capacity, utilization levels, yields and operating efficiencies; financing, supply-chain and market risks; and the other risks described in EM&T’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results, performance or achievements may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date made. EM&T undertakes no obligation to update any forward-looking statement except as required by law. Additional information concerning factors that may affect EM&T’s expectations and projections is contained in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, filed with the SEC on August 17, 2026, including the disclosures under “Risk Factors” therein, and other documents filed or to be filed with the SEC by EM&T. SEC filings are available at www.sec.gov.
: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
